Acknowledgement
이 연구는 대한민국 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구임(NRF-2020R1F1A1069711).
References
- Kang YH, Lee GY, Park CR, Cho JH, Son CG, Lee NH. A case report of Hand-foot syndrome due to sorafenib with Jaungo. J Haehwa Med 2019;28(2):54-9.
- Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71(4):787-94. https://doi.org/10.1016/j.jaad.2014.03.019
- Nikolaoua V, Syrigosa K, Saif WM. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 2016;15(12): 1625-33. https://doi.org/10.1080/14740338.2016.1238067
- Heo YS. Frequency, clinical course and risk factors of hand-foot syndrome in patients administered capecitabine containing chemotherapies. Graduate School, Yihwa University 2003:1-48.
- Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: Results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010;28(24):3824-9. https://doi.org/10.1200/JCO.2010.29.1807
- Chen M, Zhang L, Wang Q, Shen J. Pyridoxine for Prevention of Hand-Foot Syndrome Caused by Chemotherapy: A Systematic Review. PLoS One 2013;8(8):1-7.
- Han GJ, Jang MW, Seong S, Kim SS. A Case Report of Chemotherapy-Induced Hand-Foot Syndrome Treated with Modified Dohongsamul-tang. J Intern Korean Med 2018;39(2):259-67. https://doi.org/10.22246/jikm.2018.39.2.259
- Chen X. External Use of Yiqi Tongluo Treatment in Hand-Foot Syndrome Caused by Capecitabine: A Clinical Study. Zhejiang Univ Tradit Chinese Med 2015.
- Liu K. Clinical Observation of Using Modified Xiexin Decoction Combined with Porphyra Olive Oil External Use in the Prevention and Treatment of 80Cases of Kababine Related Hand Foot Syndrome. J Sichuan Tradit Chinese Med 2018; 36(9):119-21.
- Zhou L. Clinical observation of the modified Huangqi Guizhi Wuwu Tang for external use in preventing and treating 23 cases with capecitabine related hand foot syndrome. J Gansu Univ Chinese Med 2017;34(3):46-8.
- Rev Man 5 download(current version: 5.4.1) Cochrane Community.
- Kim SY, Park JE, Seo HJ, Seo HS, Son HJ, Shin CM, et al. NECA's Guidance for Undertaking Systematic Reviews and Meta-Analyses for Intervention. Seoul: NECA(National Evidence-based Healthcare Collaborating Agency) Center for New Health Technology Assessment; 2011.
- Ying H, Guo Y, Zheng L, Zhang W, Cao Q, Shen X, et al. Clinical Observation of Wuwei Xuanbi Decoction of Early Intervention on Colon Cancer Patients with Hand Foot Syndrome Cause by Capecitabine. Journal of Liaoning University of Traditional Chinese Medicine 2014; 16(10):108-10.
- Zhao CL, Chen J, Yu B, Wu XL, Dai CQ, Zhou C, et al. Effect of Modified Taohongsiwu Decoction on Patients with Chemotherapy-Induced Hand-Foot Syndrome. J Tradit Chinese Med 2014;34(1):10-4. https://doi.org/10.1016/S0254-6272(14)60047-9
- Jinlin Z, Zhidong L, Bin N, Xiangqiong M. Clinical Study of Yiqi Tongbi Prescription Combined with Siwu Decoction in Treatment of Colon Cancer Patientspostoperative Chemotherapy Related Hand Foot Syndrome. Chinese Arch Tradit Chinese Med 2019:1906-9.
- Yu R, Wu X, Jia L, Lou Y. Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, and Parallel-Controlled Trial. Integr Cancer Ther 2020;19(8):1-10. https://doi.org/10.1158/1535-7163.1.19.1
- Yanni L, Xinyi C, Aiping T, Xia Z, Li F, Huangying T, et al. External Use of Tongluo Huoxue Treatment in Hand-Foot Syndrome Caused by Capecitabine_A Clinical Study. Journal of Liaoning University of TCM 2013; 15(4):68-70.
- Qingnan M. Clinical Study on External Bath of Modified Guizhi Decoction in Treatment for Hand-foot Syndrome Caused by Apatinib. Zhejiang Univ Tradit Chinese Med 2018:1-25.
- Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011;16(10):1469-78. https://doi.org/10.1634/theoncologist.2011-0033
- National Cancer Institute. Common Terminology Criteria for Adverse Events. United States; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute: 2009, p. 1-78.
- Nathan C, Marie F, Stein K, Russell P, David C. Karnofsky Performance status scale definitions rating criteria. Oxford Textb Palliat Med 1993:109.